InsomniaPhase 3NCT00857220
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A Phase 3 study testing eszopiclone in people with Insomnia and Attention Deficit Hyperactivity Disorder, run by Sumitomo Pharma America, Inc. at 89 sites in United States.
Trial summary
A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia. Read more about this study
- Who is it for?
- Ages 6 to 17 years
- Conditions the study is for
- Insomnia, Attention Deficit Hyperactivity Disorder
- What is being tested?
- eszopiclone
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 304 participants
- Where
- 89 sitesUnited States
- Study dates
- May 2009to Oct 2011
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Subject is male or female 6 17 years of age, inclusive, at the time of consent.
- Subject must have a diagnosis of ADHD as defined by DSM-IV criteria • The diagnosis for Rollover subjects will be taken from the Screening visit of Study 190 246. Treatment naïve subjects will have these assessments performed at the Screening visit.
- Subject must have documented ADHD associated insomnia, defined as the subject or subject's parent/legal guardian having reported repeated difficulty with sleep initiation (sleep latency >30 minutes) or consolidation (wake time after sleep onset > 45 minutes),>despite adequate age appropriate time and opportunity for sleep.
- Subject has either >30 minutes latency to persistent sleep (LPS) or >45 minutes wake time after sleep onset (WASO) demonstrated by PSG.
- Subject or subject's parent/legal guardian should have reported daytime functional impairment as a result of sleep problems.
- Subject or subject's parent/legal guardian should have reported attempted and failed behavioral interventions for sleep problems, including a regular bedtime and rise time.
Show all 11Show fewer
- Subject's sleep disturbance must not be attributable to either the direct physiologic effect of a drug of abuse or misuse of a prescribed medication whether it is being used as intended or in an illicit manner.
- Female subjects ≥8 years of age must have a negative serum pregnancy test at screening
- Subject must be in good general health.
- Subject must be able to swallow tablets.
- If subjects are currently taking medication for ADHD, they must be on a stable dose and regimen for at least one month, and preferably for at least 3 months prior to the time of consent
Who cannot join
- Subject with weight <10th percentile for age and gender
- Subject has any clinically significant or unstable medical abnormality/illness
- Subject has a documented history of Bipolar I or II Disorder, major depression, conduct disorder, generalized anxiety disorder (other than obsessive-compulsive disorder) or any history of psychosis, as determined by medical or psychiatric history or as determined by clinical interview using the MINI-Kid at Visit 1.
- Subject has periodic limb movement >5 times per hour, as demonstrated on PSG.
- Subject has sleep disordered breathing, as demonstrated on PSG.
- Subject has another primary sleep disorder (or secondary sleep disorder that is causing clinical impairment or any other known or suspected medical or psychiatric condition that has affected or may affect sleep
Show all 15Show fewer
- Subject has a history of circadian rhythm disorder or will travel across ≥3 time zones more than once during the study.
- Subject has organic brain disease, or a history of febrile seizures.
- Subject is, in the opinion of the investigator, at suicidal or homicidal risk.
- Female subject who is pregnant, lactating or planning to become pregnant.
- Subject is taking any psychotropic or disallowed medications,
- Subject has a history of severe allergies to more than 1 class of medications or multiple adverse drug reactions.
- Subject has a history of allergic reaction or has a known or suspected sensitivity to racemic zopiclone, eszopiclone, or any substance that is contained in the formulation.
- Subject has a history of alcohol or substance abuse within 3 months of study participation
- Subject has participated in any investigational study within 30 days prior to study entry or is currently participating in another clinical trial, except Study 190 246.
Trial locations and contacts
89 sites in 1 country.
89 sites in 1 country
United States89 sites
Academy of Clinical Research
Arlington, Texas, 76011
Sleep Disorders Center of Georgia
Atlanta, Georgia, 30342
NorthCoast Clinical Trials, Inc.
Beachwood, Ohio, 44122
Neurobehavioral Medicine Group
Bloomfield Hills, Michigan, 48302
Neuro-Behavioral Clnical Research
Canton, Ohio, 44718
AV Institute, Inc.
Carson, California, 90746
MD
Chevy Chase, Maryland, 20815
Delta Waves, Inc.
Colorado Springs, Colorado, 80918
Clinical Innovations, Inc.
Costa Mesa, California, 92626
Pillar Clinical Research, LLC
Dallas, Texas, 75243
InSite Clinical Research
DeSoto, Texas, 75115
Mountain West Clinical Trials
Eagle, Idaho, 83616
Suburban Lung Associates, SC
Elk Grove Village, Illinois, 60007
Cutting Edge Research of Enid
Enid, Oklahoma, 72703
Precise Research Centers
Flowood, Mississippi, 39232
Sarkis Clinical Trials
Gainesville, Florida, 32607
Behavioral Research Specialists, LLC
Glendale, California, 91204
Cyn3rgy Research
Gresham, Oregon, 97030
MD Clinical
Hallandale, Florida, 3309
ActivMed Practices and Research
Haverhill, Massachusetts, 01830
Clinical Research Center of Nevada
Henderson, Nevada, 89015
Amedica Research Institute, Inc.
Hialeah, Florida, 33013
Claghorn-Lesem Research Clinic, Ltd.
Houston, Texas, 77008
Allegiant Clinical Research
Houston, Texas, 77024
MD
Houston, Texas, 77042
Sun Valley Research Center
Imperial, California, 92251
Davis Clinic
Indianapolis, Indiana, 46260
Goldpoint Clinical Research, LLC
Indianapolis, Indiana, 46260
Holston Medical Group
Kingsport, Tennessee, 37660
Eastside Therapeutic Resource
Kirkland, Washington, 98033
Lake Charles Clinical Trials
Lake Charles, Louisiana, 70601
Center for Psychiatry and Behavioral Medicine, Inc.
Las Vegas, Nevada, 89128
Behavioral Clinical Research Inc.
Lauderhill, Florida, 33319
Behavioral Clinical Research, Inc.
Lauderhill, Florida, 33319
Capstone Clinical Research
Libertyville, Illinois, 601048
Premier Psychicatric Research Institute, LLC
Lincoln, Nebraska, 68510
Midwest Children's Health Research Institute
Lincoln, Nebraska, 68516
Clinical Study Centers, LLC
Little Rock, Arkansas, 72205
Brownsboro Park Pediatrics
Louisville, Kentucky, 40207
Pediatric Neurology and Epilepsy Center
Loxahatchee Groves, Florida, 33470
Florida Clinical Research Center, LLC
Maitland, Florida, 32751
Cleveland Sleep Research Center
Middleburg Heights, Ohio, 44130
North Star Medical Research, LLC
Middleburg Heights, Ohio, 44130
AMR Baber Research, Inc.
Naperville, Illinois, 60563
Nassim, McMonigle, Mescia & Associates
New Albany, Indiana, 47150
Louisiana Research Associates, Inc.
New Orleans, Louisiana, 70114
Neurocare, Inc.
Newton, Massachusetts, 02459
ActivMed Practices and Research
North Andover, Massachusetts, 01845
Scientific Clinical Research Inc.
North Miami, Florida, 33161
Excell Research, Inc.
Oceanside, California, 92056
North County Clinical Research (NCCR)
Oceanside, California, 92056
IPS Research Company
Oklahoma City, Oklahoma, 73103
Pahl Pharmaceutical Professionals, LLC
Oklahoma City, Oklahoma, 73112
SP Research
Oklahoma City, Oklahoma, 73112
Cutting Edge Research Group
Oklahoma City, Oklahoma, 73116
Eminence Research LLC
Oklahoma City, Oklahoma, 73139
Pacific Clinical Research Medical Group
Orange, California, 92868
SDS Clinical Trials, Inc.
Orange, California, 92868
Medical Research Group of Central Florida
Orange City, Florida, 32763
Aspen Clinical Research, LLC
Orem, Utah, 84058
Florida Institute for Clinical Research, LLC
Orlando, Florida, 32822
Psychiatric Associates
Overland Park, Kansas, 66211
Pedia Research, LLC
Owensboro, Kentucky, 42301
CRI Worldwide
Philadelphia, Pennsylvania, 19139
DMI Research Inc.
Pinellas Park, Florida, 33782
The Mech Center
Plano, Texas, 75024
Oregon Center for Clinical Investigations, Inc.
Portland, Oregon, 97210
Global Medical Institutes, LLC
Princeton, New Jersey, 08540
Alliance Research Group
Richmond, Virginia, 23230
Clinical Innovations, Inc.
Riverside, California, 92506
Northwest Behavioral Research Center
Roswell, Georgia, 30076
Oregon Center for Clinical Investigations, Inc. (OCCI, Inc.)
Salem, Oregon, 97301
Road Runner Research
San Antonio, Texas, 78258
Artemis Institute for Clinical Research
San Diego, California, 92123
Clinical Innovations
San Diego, California, 92128
Neuropsychiatric Research Center of Orange County
Santa Ana, California, 92701
Apex Research Institute
Santa Ana, California, 92705
Clinical Innovations, Inc.
Santa Ana, California, 92705
Florida Sleep Institute
Spring Hill, Florida, 34609
Clinical Nuerophysiology Services, PC
Sterling Heights, Michigan, 48314
SomnoMedics, LLC
Tampa, Florida, 33607
REM Medical Clinical Research
Tucson, Arizona, 85712
Paradigm Research Professonals, LLP
Tulsa, Oklahoma, 74103
Tulsa Clinical Research
Tulsa, Oklahoma, 74104
Sleep and Behavior Medicine Institute
Vernon Hills, Illinois, 60061
Brighton Research Group, LLC
Virginia Beach, Virginia, 23452
Omega Medical Research
Warwick, Rhode Island, 02886
Elite Clinical Trials, Inc.
Wildomar, California, 92595
CRI Worldwide, LLC
Willingboro, New Jersey, 08046
About this study
Official title: A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.
Read the detailed description
This is a multi center, open label, long term safety study in pediatric subjects 6 through 17 years of age, inclusive, with a diagnosis of ADHD associated insomnia. Subjects who complete Study 190 246 (Rollover subjects) and meet the study enrollment criteria will be allowed to participate in this long term safety study. Additionally, Treatment naïve subjects will be enrolled in this long term safety study in order to meet the overall subject enrollment objective of obtaining 100 subjects with 12 months of treatment. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
- Conditions
- Insomnia, Attention Deficit Hyperactivity Disorder
- Being tested
- eszopiclone
- Keywords
- Hypnotic, Eszopiclone, Attention Deficit Hyperactivity Disorder, Insomnia, Children, Adolescent
- Medical subject headings
- Sleep Initiation and Maintenance Disorders, Attention Deficit Disorder with Hyperactivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
eszopicloneDrug
One 2 mg tablet per day for 12 months
eszopicloneDrug
one 3mg tablet per day for 12 months
| Study group | Role | What they receive |
|---|---|---|
| 2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs) | Experimental | Not described Receives: Drug: eszopiclone |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Incidence of Adverse Events
Measured: 12 Months (from the 1st dose to the end of study)
Secondary outcomes (13)
Overall Incidence of Skin Reactions: Number of Events
Measured: 12 Months (from the 1st dose to the end of study)
Overall Incidence of Skin Reactions: Number of Participant Affected
Measured: 12 Months (from the 1st dose to the end of study)
Columbia-Suicide Severity Rating Scale (C-SSRS) Item Responses
The C-SSRS is a physician-completed scale to assess any suicidal ideation and suicidal behavior. The C-SSRS contained questions about suicidal behavior and suicidal ideation. Subjects were placed into categories for suicidal behavior and for suicidal ideation based on their responses to various questions. Any suicidality was defined as suicidal behavior or suicidal ideation. The suicidal behavior categories were determined based on the response to the questions under suicidal behavior (Completed Suicide, Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Acts or Behavior).The suicidal ideation categories were determined by examining the response to 5 questions under suicidal ideation (Wish to be Dead, Nonspecific Active Suicidal Thoughts, Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act, Active Suicidal Ideation with Some Intent to Act, without Specific Plan, Active Suicidal Ideation with Specific Plan and Intent).
Measured: 12 Months
Change From Baseline in Coding Copy Subtest A or B, or Digit Symbol Substitution Test (DSST)at Month 12
These tests are standardized information processing tasks to assess recognition and recoding of sensory information. The subject was given 90 seconds to complete as many substitutions of symbols as possible according to a code provided on top of the sheet. The Coding Copy Subtest A was used for subjects 6 to 7 years of age, the Coding Copy Subtest B was used for subjects 8 to 16 years of age, and the DSST was used for subjects 17 years of age. The DSST consists of rows containing small blank squares, each paired with a randomly assigned numbers 1-9. Above the rows is a key that pairs each number with a symbol. The subject must fill in the blank spaces with the matching symbol that is in the key. For the Subcopy tests the subject simply copies the symbol above each empty square. Scaled scores are used to account for age differences among test takers. Scaled scores range from 1 to 19, and higher scores indicate higher cognitive function.
Measured: Baseline and 12 Months (from the 1st dose to the end of study)
Clinical Global Impression (CGI) Improvement Score as Assessed by Parent/Caregiver or Child at Month 12
A 7-point scale was used for improvement with numeric values assigned to each of the responses: very much improved (1), much improved (2), minimally improved (3), no change (4), minimally worse (5), much worse (6), and very much worse (7).
Measured: Baseline and 12 Months (from the 1st dose to the end of study)
Change From Baseline at Month 12 in Subjective Sleep Latency (SL)
Sleep latency is the amount of time it takes to fall asleep after the lights have been turned off.
Measured: Baseline and 12 Months (from the 1st dose to the end of study)
Change From Baseline in Child Behavior Checklist (CBCL)
CBCL was completed by parents or guardians who saw the child in home-like settings. It includes several competence items, open-ended items for describing the child's illnesses, disabilities, concerns about the child, best things about the child, and several items to rate behavioral, emotional, and social problems. Responses are recorded on a Likert scale: 0 = Not True, 1 = Somewhat or Sometimes True, 2 = Very True or Often True. The checklist contains 120 questions. The standardized score is computed by determining the z-score by subtracting the mean for the subject's age group and gender from the raw score and then dividing this by the standard deviation for the subject's age group and gender. Next, multiply the zscore by 15 and then add 100. For activities scale, social scale, school scale, and total competence scale, higher values indicate higher competencies. For Internalizing problems, externalizing problems, and total problems, higher values indicate more problems.
Measured: Baseline and 12 Months (from the 1st dose to the end of study)
Change From Baseline in Pediatric Daytime Sleepiness Scale (PDSS)at Month 12
The PDSS total score ranges from a low of 0 where the individual is endorsing each item at the lowest level of daytime sleepiness to a high of 32 where the individual is endorsing each item at the highest level of daytime sleepiness.
Measured: Baseline and 12 Months (from the 1st dose to the end of study)
Change From Baseline in Conners' Continuous Performance Test II (CCPT II)
The CCPT-II is a computer-based 14-minute, visual-performance task. During an administration, respondents were required to press the space bar or click the mouse whenever any letter except the target letter appears on the screen. The speed at which the letters were presented varied during the administration. There were 6 blocks, with 3 sub-blocks, each containing 20 trials (letter presentations). The interstimulus intervals (ISIs) were 1, 2, and 4 seconds with a display time of 250 milliseconds. The order in which the different ISIs were presented varied between blocks. Conners' CCPT-II provides the following measures:% Omissions,% Commissions, Hit Reaction Time, Hit Reaction Time Standard Error,Variability of Standard Error, Detectability (d'), Response Style (beta), Perseverations, Hit Reaction Time Block Change (Vigilance Measure), Hit Standard Error Block Change (Vigilance Measure), Hit Reaction Time ISI change, and Hit Standard Error ISI Change, Confidence Index.
Measured: Baseline and 12 Months (from the 1st dose to the end of study)
Change From Baseline at Month 12 in Subjective Wake Time After Sleep Onset (WASO)
The sleep questionnaire, a Sponsor produced questionnaire used in previous eszopiclone studies, asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of the subject's sleep over a predefined time period. WASO was assessed based on the responses to the sleep questionnaire.
Measured: Baseline and 12 Months (from the 1st dose to the end of study)
Change From Baseline at Month 12 in Subjective Number of Awakening After Sleep Onset (NAASO)
The sleep questionnaire, a Sponsor produced questionnaire used in previous eszopiclone studies, asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of the subject's sleep over a predefined time period. NAASO was assessed based on the responses to the sleep questionnaire.
Measured: Baseline and 12 Months (from the 1st dose to the end of study)
Change From Baseline at Month 12 in Subjective Total Sleep Time (TST).
The sleep questionnaire, a Sponsor produced questionnaire used in previous eszopiclone studies, asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of the subject's sleep over a predefined time period. TST was assessed based on the responses to the sleep questionnaire.
Measured: Baseline and 12 Months (from the 1st dose to the end of study)
Change From Baseline in Pediatric Quality of Life Scale
The SF-10™ Health Survey for Children is a 10-item care-giver completed assessment designed to measure children's health-related quality of life. The scale asked questions about the child's physical wellness, feelings, behavior, and activities at school and with family and friends. The SF-10 physical and psychosocial summary measures were scored such that higher scores indicated more favorable functioning. The Physical Summary Score is computed by summing values for questions 1, 2a, 2b, 3 and 5 and standardizing scores by normalizing to a total possible score of 0-100 with higher scores representing more positive indications. The Psychosocial Summary Score is computed by summing questions 4, 6, 7, 8, and 9 and standardizing scores by normalizing to a total possible score of 0-100 with higher scores representing more positive indications.
Measured: Baseline and 12 Months (from the 1st dose to the end of study)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Mar 2009 (estimated)
- Study startMay 2009
- Primary completionOct 2011
- Study completionOct 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for InsomniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 304 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00857220
- Sponsor's protocol ID
- 190-247
- Status last verified
- Sep 2017
- First submitted
- 4 Mar 2009
- Last updated
- 26 Oct 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Sangal RB, Blumer JL, Lankford DA, Grinnell TA, Huang H. Eszopiclone for insomnia associated with attention-deficit/hyperactivity disorder. Pediatrics. 2014 Oct;134(4):e1095-103. doi: 10.1542/peds.2013-4221.
PubMed 25266438
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
- ClinicalTrials.gov ID
- NCT00857220
- Acronym / sponsor ID
- 190-247
- Conditions
- Insomnia, Attention Deficit Hyperactivity Disorder
- Keywords
- Hypnotic, Eszopiclone, Attention Deficit Hyperactivity Disorder, Insomnia, Children, Adolescent
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 304 participants (actual)
- Lead sponsor
- Sumitomo Pharma America, Inc.Industry (pharma, biotech, devices)
- Study start
- May 2009
- Primary completion
- Oct 2011 (actual)
- Study completion
- Oct 2011 (actual)
- First posted
- 6 Mar 2009 (estimated)
- Results
- Posted 22 Jul 2013
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.
Detailed description
This is a multi center, open label, long term safety study in pediatric subjects 6 through 17 years of age, inclusive, with a diagnosis of ADHD associated insomnia. Subjects who complete Study 190 246 (Rollover subjects) and meet the study enrollment criteria will be allowed to participate in this long term safety study. Additionally, Treatment naïve subjects will be enrolled in this long term safety study in order to meet the overall subject enrollment objective of obtaining 100 subjects with 12 months of treatment. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs) | Experimental | Drug: eszopiclone |
Who may qualify
- Ages
- 6 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (11 listed)
- Subject is male or female 6 17 years of age, inclusive, at the time of consent.
- Subject must have a diagnosis of ADHD as defined by DSM-IV criteria • The diagnosis for Rollover subjects will be taken from the Screening visit of Study 190 246. Treatment naïve subjects will have these assessments performed at the Screening visit.
- Subject must have documented ADHD associated insomnia, defined as the subject or subject's parent/legal guardian having reported repeated difficulty with sleep initiation (sleep latency >30 minutes) or consolidation (wake time after sleep onset > 45 minutes),>despite adequate age appropriate time and opportunity for sleep.
- Subject has either >30 minutes latency to persistent sleep (LPS) or >45 minutes wake time after sleep onset (WASO) demonstrated by PSG.
- Subject or subject's parent/legal guardian should have reported daytime functional impairment as a result of sleep problems.
Key exclusion criteria (15 listed)
- Subject with weight <10th percentile for age and gender
- Subject has any clinically significant or unstable medical abnormality/illness
- Subject has a documented history of Bipolar I or II Disorder, major depression, conduct disorder, generalized anxiety disorder (other than obsessive-compulsive disorder) or any history of psychosis, as determined by medical or psychiatric history or as determined by clinical interview using the MINI-Kid at Visit 1.
- Subject has periodic limb movement >5 times per hour, as demonstrated on PSG.
- Subject has sleep disordered breathing, as demonstrated on PSG.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| eszopicloneOne 2 mg tablet per day for 12 months | Drug | 2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs) |
| eszopicloneone 3mg tablet per day for 12 months | Drug | 2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs) |
Primary outcome
Overall Incidence of Adverse Events
Time frame: 12 Months (from the 1st dose to the end of study)
13 secondary outcomes
Overall Incidence of Skin Reactions: Number of Events
Time frame: 12 Months (from the 1st dose to the end of study)
Overall Incidence of Skin Reactions: Number of Participant Affected
Time frame: 12 Months (from the 1st dose to the end of study)
Columbia-Suicide Severity Rating Scale (C-SSRS) Item Responses
Time frame: 12 Months
Change From Baseline in Coding Copy Subtest A or B, or Digit Symbol Substitution Test (DSST)at Month 12
Time frame: Baseline and 12 Months (from the 1st dose to the end of study)
Clinical Global Impression (CGI) Improvement Score as Assessed by Parent/Caregiver or Child at Month 12
Time frame: Baseline and 12 Months (from the 1st dose to the end of study)
Change From Baseline at Month 12 in Subjective Sleep Latency (SL)
Time frame: Baseline and 12 Months (from the 1st dose to the end of study)
Change From Baseline in Child Behavior Checklist (CBCL)
Time frame: Baseline and 12 Months (from the 1st dose to the end of study)
Change From Baseline in Pediatric Daytime Sleepiness Scale (PDSS)at Month 12
Time frame: Baseline and 12 Months (from the 1st dose to the end of study)
Change From Baseline in Conners' Continuous Performance Test II (CCPT II)
Time frame: Baseline and 12 Months (from the 1st dose to the end of study)
Change From Baseline at Month 12 in Subjective Wake Time After Sleep Onset (WASO)
Time frame: Baseline and 12 Months (from the 1st dose to the end of study)
Change From Baseline at Month 12 in Subjective Number of Awakening After Sleep Onset (NAASO)
Time frame: Baseline and 12 Months (from the 1st dose to the end of study)
Change From Baseline at Month 12 in Subjective Total Sleep Time (TST).
Time frame: Baseline and 12 Months (from the 1st dose to the end of study)
Change From Baseline in Pediatric Quality of Life Scale
Time frame: Baseline and 12 Months (from the 1st dose to the end of study)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 25266438Sangal RB, Blumer JL, Lankford DA, Grinnell TA, Huang H. Eszopiclone for insomnia associated with attention-deficit/hyperactivity disorder. Pediatrics. 2014 Oct;134(4):e1095-103. doi: 10.1542/peds.2013-4221.
Related trials for Insomnia
Recruiting
Addressing Nocturia in Older Women Utilizing Behavioral Sleep Intervention and Brief Mindfulness
Nocturia, Insomnia
Not yet recruiting
A Transdiagnostic Sleep Health Intervention for Veterans With PTSD
Stress Disorders, Post-Traumatic, Sleep Initiation and Maintenance Disorders
Recruiting
Effect of Cyclic Sighing Breathing Exercise on CRBD, Pain, and Sleep Quality in Patients Undergoing TUR
Transurethral Resection of Bladder Tumor, Transurethral Resection of the Prostate (TURP)
Recruiting
Evaluation of Cognitive Behavioral Therapy for Insomnia (CBT-I) in Individuals With Mild Traumatic Brain Injury (mTBI)
Sleep Architecture, Mild Traumatic Brain Injury
RecruitingPhase 3
A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the Day
Insomia Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
89 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing eszopiclone in people with Insomnia and Attention Deficit Hyperactivity Disorder, run by Sumitomo Pharma America, Inc. at 89 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Oct 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 89 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Jul 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Incidence of Adverse Events (time frame: 12 Months (from the 1st dose to the end of study)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00857220, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2017.